

Peyman Hadji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/109418/publications.pdf>

Version: 2024-02-01

49
papers

1,856
citations

236833

25
h-index

265120

42
g-index

52
all docs

52
docs citations

52
times ranked

2233
citing authors

#	ARTICLE	IF	CITATIONS
1	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry. <i>European Journal of Cancer</i> , 2022, 172, 13-21.	1.3	1
2	Impact of breast cancer and its treatment on bone loss and fracture risk – pathophysiology and management. , 2021, , 1395-1406.		0
3	Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. <i>Journal of Bone Oncology</i> , 2021, 28, 100355.	1.0	30
4	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021, 155, 1-12.	1.3	39
5	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. <i>Cancers</i> , 2020, 12, 3021.	1.7	6
6	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1134-1142.	0.8	4
7	Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2487-2506.	1.8	35
8	Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. <i>International Journal of Cancer</i> , 2019, 144, 877-885.	2.3	31
9	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10.	1.7	43
10	The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIB 4EVER trial. <i>Journal of Bone Oncology</i> , 2019, 14, 100199.	1.0	3
11	Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 237-245.	0.8	20
12	Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	0.8	23
13	Bone health during endocrine therapy for cancer. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 901-910.	5.5	85
14	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	0.9	54
15	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	0.9	56
16	Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1119-1128.	0.8	3
17	Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. <i>Bone</i> , 2018, 114, 109-115.	1.4	14
18	Pregnancy-associated transient osteoporosis of the hip: results of a case-control study. <i>Archives of Osteoporosis</i> , 2017, 12, 11.	1.0	38

#	ARTICLE	IF	CITATIONS
19	Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. <i>Journal of Bone Oncology</i> , 2017, 7, 1-12.	1.0	181
20	Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer. <i>Cancer Treatment Reviews</i> , 2017, 61, 23-34.	3.4	28
21	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 3-10.	3.1	127
22	Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications. <i>Supportive Care in Cancer</i> , 2017, 25, 549-558.	1.0	19
23	Update Breast Cancer 2017 – Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1281-1290.	0.8	19
24	Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 92.	2.2	21
25	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65.	1.1	27
26	The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 151-157.	1.1	32
27	Cancer Treatment-Induced Bone Loss in women with breast cancer. <i>BoneKEy Reports</i> , 2015, 4, 692.	2.7	36
28	Effects of Exemestane and Tamoxifen Treatment on Bone Texture Analysis Assessed by TBS in Comparison With Bone Mineral Density Assessed by DXA in Women With Breast Cancer. <i>Journal of Clinical Densitometry</i> , 2014, 17, 66-71.	0.5	48
29	Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 343-351.	1.1	11
30	Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1671-1680.	1.2	28
31	Zoledronic acid and atorvastatin inhibit α 23-mediated adhesion of breast cancer cells. <i>Journal of Bone Oncology</i> , 2014, 3, 10-17.	1.0	16
32	Importance of durational hormone therapy in breast cancer patients in Germany: Retrospective database analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1603-1603.	0.8	0
33	Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 101-111.	2.0	46
34	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. <i>Journal of the National Cancer Institute</i> , 2013, 105, 654-663.	3.0	88
35	The Effect of Age, Sex Hormones, and Bone Turnover Markers on Calcaneal Quantitative Ultrasonometry in Healthy German Men. <i>Journal of Clinical Densitometry</i> , 2013, 16, 320-328.	0.5	21
36	Regulation of VEGF by mevalonate pathway inhibition in breast cancer. <i>Journal of Bone Oncology</i> , 2013, 2, 110-115.	1.0	10

#	ARTICLE	IF	CITATIONS
37	Bone Oncology"An emerging multi-disciplinary specialty. <i>Journal of Bone Oncology</i> , 2012, 1, 1.	1.0	0
38	Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg. <i>Contraception</i> , 2012, 86, 359-365.	0.8	2
39	Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES). <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1089-1096.	1.1	13
40	Consensus on the utility of bone markers in the malignant bone disease setting. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 411-432.	2.0	84
41	The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1015-1025.	1.2	42
42	Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 156-166.	2.0	122
43	Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor. <i>Breast Care</i> , 2010, 5, 290-296.	0.8	9
44	Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 73-82.	2.0	144
45	The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. <i>European Journal of Cancer</i> , 2009, 45, 3205-3212.	1.3	66
46	Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. <i>Patient Preference and Adherence</i> , 2009, 3, 25-30.	0.8	29
47	Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). <i>Joint Bone Spine</i> , 2008, 75, 303-310.	0.8	57
48	Reducing the Risk of Cancer Treatment-Associated Bone Loss in Patients With Breast Cancer. <i>Seminars in Oncology</i> , 2007, 34, S4-S10.	0.8	24
49	Age-Associated Changes in Bone Ultrasonometry of the os calcis. <i>Journal of Clinical Densitometry</i> , 2002, 5, 297-303.	0.5	7